Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Has Average Target Price of $595.20

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been given a consensus recommendation of “Hold” by the thirteen analysts that are presently covering the stock, Marketbeat.com reports. Ten analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $602.27.

A number of analysts recently commented on MEDP shares. Barclays set a $600.00 price target on Medpace in a research note on Thursday, July 23rd. Truist Financial upped their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Jefferies Financial Group restated a “hold” rating on shares of Medpace in a report on Monday, September 14th. Leerink Partners set a $620.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: UBS upgraded Medpace from “sell” to “neutral” (effectively “hold”) and raised its price target to $673 from $405. The revised target remains above the recent trading level, suggesting UBS sees less downside risk than previously expected. UBS upgrades Medpace and raises price target
• Positive Sentiment: Medpace’s latest reported quarter showed solid momentum, with revenue increasing 17.2% year over year to $707.3 million and adjusted earnings of $4.25 per share exceeding analyst expectations. Management’s fiscal 2026 earnings guidance remains supportive of the long-term growth narrative. Medpace reports 17.2 percent revenue growth
• Neutral Sentiment: Analyst sentiment remains mixed. Several firms have “hold” ratings, while others maintain bullish views; the broader consensus is near a hold rating, indicating that expectations for Medpace’s strong growth are already reflected in its relatively high valuation.
• Negative Sentiment: CEO August Troendle sold 21,966 shares for approximately $13.7 million on September 30, following the sale of 26,701 shares worth about $16.6 million one day earlier. The combined sales totaled roughly $30.3 million and reduced his direct ownership by about 13% across the two transactions. Additional smaller reported sales add to concerns about insider confidence, even though Troendle still owns a substantial stake. Medpace CEO stock sale SEC filing

Insider Transactions at Medpace

In other Medpace news, CEO August Troendle sold 49,018 shares of the firm’s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the completion of the transaction, the chief executive officer owned 433,372 shares of the company’s stock, valued at approximately $272,205,286.92. This trade represents a 10.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 336,140 shares of company stock valued at $208,008,328 in the last ninety days. 20.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MEDP. Johnson Financial Group Inc. bought a new stake in Medpace during the second quarter worth about $27,000. Jones Financial Companies Lllp bought a new position in shares of Medpace during the second quarter valued at approximately $30,000. Allied Private Wealth LLC purchased a new position in shares of Medpace during the second quarter valued at approximately $31,000. Kilter Group LLC purchased a new position in shares of Medpace during the second quarter valued at approximately $31,000. Finally, Basecamp Wealth Advisors LLC lifted its holdings in shares of Medpace by 187.5% during the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after purchasing an additional 45 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Down 4.2%

Shares of Medpace stock opened at $598.08 on Tuesday. The firm has a market cap of $16.69 billion, a PE ratio of 35.06, a price-to-earnings-growth ratio of 2.78 and a beta of 1.18. Medpace has a 12-month low of $373.00 and a 12-month high of $677.90. The company’s fifty day simple moving average is $599.99 and its two-hundred day simple moving average is $520.63.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts expect that Medpace will post 17.54 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.